Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?

Details

Serval ID
serval:BIB_4448266B5C3F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
Journal
Current opinion in biotechnology
Author(s)
Martin-Lluesma S., Graciotti M., Grimm A.J., Boudousquié C., Chiang C.L., Kandalaft L.E.
ISSN
1879-0429 (Electronic)
ISSN-L
0958-1669
Publication state
Published
Issued date
22/04/2020
Peer-reviewed
Oui
Volume
65
Pages
190-196
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: aheadofprint
Abstract
New treatments are urgently needed in patients with ovarian cancer (OC), as diagnosis is delayed in many instances, resulting in 85% recurrence of the disease following surgery and standard chemotherapy. OC is considered to be an immunological type of cancer, despite its limited response to current immunotherapy options, including vaccination. Thus, additional interventions may improve their efficacy. Dendritic cells (DCs) are the most widely used cellular vaccination therapy in patients with OC due to their crucial role in the initiation and development of immune response. There are viable options for DC-vaccination with a favorable toxicity profile, but specific alternatives should consider the limited therapeutic effectiveness of DC-vaccination in OC treatment. In this respect, B-cells and macrophages provide additional possibilities that may be explored for immunotherapy. Here we consider the current state-of-the-art of immunotherapy strategies for OC treatment and evaluate their potential for future improvements.
Pubmed
Create date
02/05/2020 15:24
Last modification date
17/09/2020 6:26
Usage data